COVID-19 has ushered in new challenges when conducting clinical trials, but mid-tier biotech companies have different needs than large pharmaceutical companies. When companies are conducting studies for therapeutic areas such as oncology, or clinical trials for next-generation therapies, a smaller sponsor requires a partner that is nimble, fast-acting, and flexible, as well as transparent. Communicating what is required is vital, but even more, having a partner that can communicate what is possible is key.
Tune into our DIA- hosted webinar where Catalyst Oncology’s Vice President of Oncology Drug Development, Andrew Zupnick, PhD, and Executive Director of Oncology Drug Development, Susan Albert, alongside X4 Pharmaceuticals’ Senior Vice President of Development Operations, Carrie Melvin, and Medidata Solutions’ Senior Director, Ted Kirby, outline the key areas of support needed by mid-tier biotech companies for successful partnerships with CROs.
- A Sponsor’s perspective on the decision making criteria for selecting a CRO partner
- Need for a niche CRO solution, based on the growth and increased complexities of oncology studies
- Technology investments and capabilities that allow CROs to adapt to meet the unique needs of biotechs
- Understand the unique needs of small and midsize biotech companies when conducting oncology studies
- Recognize the need for an adaptive and responsive CRO amidst the current landscape and increased demand within the growing biotechnology industry
- Learn CRO best practices for adapting to the specific needs of small and midsize biotechs
- Tailor operational and technological approaches to planning, launching, and conducting studies for a growing market